{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:58:10Z","timestamp":1790402290917,"version":"4.1.0"},"reference-count":91,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100002608","name":"American Thyroid Association","doi-asserted-by":"publisher","award":["THYROIDGRANT2020-0000000169"],"award-info":[{"award-number":["THYROIDGRANT2020-0000000169"]}],"id":[{"id":"10.13039\/100002608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"HHS | National Institutes of Health","doi-asserted-by":"publisher","award":["K08 DK129829"],"award-info":[{"award-number":["K08 DK129829"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Aramont Charitable Foundation"},{"DOI":"10.13039\/100014547","name":"Parker Institute for Cancer Immunotherapy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014547","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Immune checkpoint inhibitor (ICI) immunotherapy leverages the body\u2019s own immune system to attack cancer cells but leads to unwanted autoimmune side effects in up to 60% of patients. Such immune-related adverse events (IrAEs) may lead to treatment interruption, permanent organ dysfunction, hospitalization, and premature death. Thyroiditis is one of the most common IrAEs, but the cause of thyroid IrAEs remains unknown. In this study, we use a new, physiologically relevant mouse model of ICI-associated autoimmunity to identify a key role for type 3 immune cells in the development of thyroid IrAEs. Multiple lineages of IL-17A\u2013producing T cells expand in thyroid tissue with ICI treatment. Intrathyroidal IL-17A\u2013producing innate-like \u03b3\u03b4T17 cells were increased in tumor-free mice, whereas adaptive Th17 cells were also prominent in tumor-bearing mice, following ICI treatment. Furthermore, Ab-based inhibition of IL-17A, a clinically available therapy, significantly reduced thyroid IrAE development in ICI-treated mice with and without tumor challenge. Finally, combination of IL-17A neutralization with ICI treatment in multiple tumor models did not reduce ICI antitumor efficacy. These studies suggest that targeting Th17 and \u03b3\u03b4T17 cell function via the IL-17A axis may reduce IrAEs without impairing ICI antitumor efficacy and may be a generalizable strategy to address type 3 immune-mediated IrAEs.<\/jats:p>","DOI":"10.4049\/jimmunol.2200244","type":"journal-article","created":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T11:13:59Z","timestamp":1657797239000},"page":"696-709","source":"Crossref","is-referenced-by-count":52,"title":["Inhibition of IL-17A Protects against Thyroid Immune-Related Adverse Events while Preserving Checkpoint Inhibitor Antitumor Efficacy"],"prefix":"10.1093","volume":"209","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4744-6566","authenticated-orcid":false,"given":"Melissa G","family":"Lechner","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Diabetes, and Metabolism, UCLA David Geffen School of Medicine , Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8915-0296","authenticated-orcid":false,"given":"Mandy I","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology, and Molecular Genetics, UCLA David Geffen School of Medicine , Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anushi Y","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology, and Molecular Genetics, UCLA David Geffen School of Medicine , Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4402-0025","authenticated-orcid":false,"given":"Aline T","family":"Hoang","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology, and Molecular Genetics, UCLA David Geffen School of Medicine , Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Yakobian","sequence":"additional","affiliation":[{"name":"Saint Louis University School of Medicine , St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9564-8691","authenticated-orcid":false,"given":"Michael","family":"Astourian","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology, and Molecular Genetics, UCLA David Geffen School of Medicine , Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marissa S","family":"Pioso","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology, and Molecular Genetics, UCLA David Geffen School of Medicine , Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4067-9399","authenticated-orcid":false,"given":"Eduardo D","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"Department of Pathology, UCLA David Geffen School of Medicine , Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0703-2366","authenticated-orcid":false,"given":"Ethan C","family":"McCarthy","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology, and Molecular Genetics, UCLA David Geffen School of Medicine , Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willy","family":"Hugo","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Medicine, UCLA David Geffen School of Medicine , Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9929-0188","authenticated-orcid":false,"given":"Trevor E","family":"Angell","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Diabetes, USC Keck School of Medicine , Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8865-3548","authenticated-orcid":false,"given":"Alexandra","family":"Drakaki","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, UCLA David Geffen School of Medicine , Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3669-8458","authenticated-orcid":false,"given":"Antoni","family":"Ribas","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, UCLA David Geffen School of Medicine , Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen A","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology, and Molecular Genetics, UCLA David Geffen School of Medicine , Los Angeles, CA"},{"name":"Division of Pediatric Endocrinology, UCLA David Geffen School of Medicine , Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,8,15]]},"reference":[{"key":"2025021008250354000_r1","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov."},{"key":"2025021008250354000_r2","doi-asserted-by":"crossref","first-page":"e192535","DOI":"10.1001\/jamanetworkopen.2019.2535","article-title":"Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs","volume":"2","author":"Haslam","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"2025021008250354000_r3","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"2025021008250354000_r4","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/ijc.32132","article-title":"A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors","volume":"145","author":"Arnaud-Coffin","year":"2019","journal-title":"Int. J. Cancer"},{"key":"2025021008250354000_r5","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"2025021008250354000_r6","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1055\/a-0843-3366","article-title":"A Systematic Review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors","volume":"51","author":"de Filette","year":"2019","journal-title":"Horm. Metab. Res."},{"key":"2025021008250354000_r7","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol."},{"key":"2025021008250354000_r8","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1158\/2326-6066.CIR-18-0487","article-title":"The balancing act between cancer immunity and autoimmunity in response to immunotherapy","volume":"6","author":"Young","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"2025021008250354000_r9","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1089\/thy.2018.0116","article-title":"Immune-related thyroiditis with immune checkpoint inhibitors","volume":"28","author":"Iyer","year":"2018","journal-title":"Thyroid"},{"key":"2025021008250354000_r10","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1210\/jc.2017-00448","article-title":"Pembrolizumab-induced thyroiditis: comprehensive clinical review and insights into underlying involved mechanisms","volume":"102","author":"Delivanis","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2025021008250354000_r11","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1158\/2326-6066.CIR-18-0245","article-title":"Autoantibody development under treatment with immune-checkpoint inhibitors","volume":"7","author":"de Moel","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"2025021008250354000_r12","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1158\/2326-6066.CIR-18-0613","article-title":"The impact of high-dose glucocorticoids on the outcome of immune-checkpoint inhibitor\u2013related thyroid disorders","volume":"7","author":"Ma","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"2025021008250354000_r13","doi-asserted-by":"crossref","first-page":"102285","DOI":"10.1016\/j.jaut.2019.05.013","article-title":"Analysis of the PD-1\/PD-L1 axis in human autoimmune thyroid disease: insights into pathogenesis and clues to immunotherapy associated thyroid autoimmunity","volume":"103","author":"\u00c1lvarez-Sierra","year":"2019","journal-title":"J. Autoimmun."},{"key":"2025021008250354000_r14","doi-asserted-by":"crossref","first-page":"eabb7495","DOI":"10.1126\/scitranslmed.abb7495","article-title":"CD4+ T cells are essential for the development of destructive thyroiditis induced by anti\u2013PD-1 antibody in thyroglobulin-immunized mice","volume":"13","author":"Yasuda","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"2025021008250354000_r15","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1089\/thy.2020.0075","article-title":"Immune checkpoint inhibitor-induced thyroiditis is associated with increased intrathyroidal T lymphocyte subpopulations","volume":"30","author":"Kotwal","year":"2020","journal-title":"Thyroid"},{"key":"2025021008250354000_r16","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.gendis.2017.11.002","article-title":"Unique cytologic features of thyroiditis caused by immune checkpoint inhibitor therapy for malignant melanoma","volume":"5","author":"Angell","year":"2018","journal-title":"Genes Dis."},{"key":"2025021008250354000_r17","doi-asserted-by":"crossref","first-page":"606056","DOI":"10.3389\/fimmu.2021.606056","article-title":"Pembrolizumab-induced thyroiditis shows PD-L1expressing histiocytes and infiltrating T cells in thyroid tissue\u2014a case report","volume":"12","author":"Jabkowski","year":"2021","journal-title":"Front. Immunol."},{"key":"2025021008250354000_r18","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13044-018-0046-9","article-title":"Role of the T and B lymphocytes in pathogenesis of autoimmune thyroid diseases","volume":"11","author":"Rydzewska","year":"2018","journal-title":"Thyroid Res."},{"key":"2025021008250354000_r19","doi-asserted-by":"crossref","first-page":"5135","DOI":"10.1210\/en.2009-0434","article-title":"T helper type 17 immune response plays an indispensable role for development of iodine-induced autoimmune thyroiditis in nonobese diabetic-H2h4 mice","volume":"150","author":"Horie","year":"2009","journal-title":"Endocrinology"},{"key":"2025021008250354000_r20","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.cyto.2016.02.011","article-title":"Circulating Th17 cytokine levels are altered in Hashimoto\u2019s thyroiditis","volume":"80","author":"Konca Degertekin","year":"2016","journal-title":"Cytokine"},{"key":"2025021008250354000_r21","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/j.1365-3083.2010.02425.x","article-title":"Differentiation imbalance of Th1\/Th17 in peripheral blood mononuclear cells might contribute to pathogenesis of Hashimoto\u2019s thyroiditis","volume":"72","author":"Shi","year":"2010","journal-title":"Scand. J. Immunol."},{"key":"2025021008250354000_r22","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1172\/JCI34523","article-title":"Mechanisms of an autoimmunity syndrome in mice caused by a dominant mutation in Aire","volume":"118","author":"Su","year":"2008","journal-title":"J. Clin. Invest."},{"key":"2025021008250354000_r23","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1158\/2159-8290.CD-19-1409","article-title":"Overcoming Genetically Based Resistance Mechanisms to PD-1 Blockade","volume":"10","author":"Torrejon","year":"2020","journal-title":"Cancer Discov."},{"key":"2025021008250354000_r24","doi-asserted-by":"crossref","first-page":"G109","DOI":"10.1152\/ajpgi.00214.2005","article-title":"T cell-induced inflammation of the small and large intestine in immunodeficient mice","volume":"290","author":"Ostanin","year":"2006","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"2025021008250354000_r25","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1158\/2326-6066.CIR-16-0060","article-title":"Response to programmed cell death-1 blockade in a murine melanoma syngeneic model requires costimulation, CD4, and CD8 T cells","volume":"4","author":"Homet Moreno","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"2025021008250354000_r26","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1126\/science.1123497","article-title":"Evidence for a functional second thymus in mice","volume":"312","author":"Terszowski","year":"2006","journal-title":"Science"},{"key":"2025021008250354000_r27","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","article-title":"Comprehensive integration of single-cell data","volume":"177","author":"Stuart","year":"2019","journal-title":"Cell"},{"key":"2025021008250354000_r28","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1126\/science.aad0501","article-title":"Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq","volume":"352","author":"Tirosh","year":"2016","journal-title":"Science"},{"key":"2025021008250354000_r29","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/1471-2105-14-128","article-title":"Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool","volume":"14","author":"Chen","year":"2013","journal-title":"BMC Bioinformatics"},{"key":"2025021008250354000_r30","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1038\/ni1008-1091","article-title":"The Immunological Genome Project: networks of gene expression in immune cells","volume":"9","author":"Heng","year":"2008","journal-title":"Nat. Immunol."},{"key":"2025021008250354000_r31","doi-asserted-by":"crossref","first-page":"5288","DOI":"10.1158\/0008-5472.CAN-16-0194","article-title":"Assessing immune-related adverse events of efficacious combination immunotherapies in preclinical models of cancer","volume":"76","author":"Liu","year":"2016","journal-title":"Cancer Res."},{"key":"2025021008250354000_r32","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41422-018-0012-z","article-title":"Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice","volume":"28","author":"Du","year":"2018","journal-title":"Cell Res."},{"key":"2025021008250354000_r33","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1089\/thy.2016.0092","article-title":"Exacerbation of autoimmune thyroiditis by CTLA-4 blockade: a role for IFN\u03b3-induced indoleamine 2, 3-dioxygenase","volume":"26","author":"Sharma","year":"2016","journal-title":"Thyroid"},{"key":"2025021008250354000_r34","doi-asserted-by":"crossref","first-page":"e0246168","DOI":"10.1371\/journal.pone.0246168","article-title":"A novel mouse model for checkpoint inhibitor-induced adverse events","volume":"16","author":"Adam","year":"2021","journal-title":"PLoS One"},{"key":"2025021008250354000_r35","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1001\/jamaoncol.2018.5860","article-title":"Profiling preexisting antibodies in patients treated with anti-PD-1 therapy for advanced non-small cell lung cancer","volume":"5","author":"Toi","year":"2019","journal-title":"JAMA Oncol."},{"key":"2025021008250354000_r36","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3389\/fmed.2019.00119","article-title":"Biomarkers for immune checkpoint inhibitor-mediated tumor response and adverse events","volume":"6","author":"Nakamura","year":"2019","journal-title":"Front. Med. (Lausanne)"},{"key":"2025021008250354000_r37","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.2337\/dbi18-0002","article-title":"Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors","volume":"67","author":"Bluestone","year":"2018","journal-title":"Diabetes"},{"key":"2025021008250354000_r38","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ejca.2020.02.049","article-title":"Human leucocyte antigen DR15, a possible predictive marker for immune checkpoint inhibitor-induced secondary adrenal insufficiency","volume":"130","author":"Yano","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"2025021008250354000_r39","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejca.2018.11.009","article-title":"Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors","volume":"107","author":"Hasan Ali","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"2025021008250354000_r40","doi-asserted-by":"crossref","first-page":"12288","DOI":"10.1073\/pnas.1922867117","article-title":"Polygenic risk for skin autoimmunity impacts immune checkpoint blockade in bladder cancer","volume":"117","author":"Khan","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2025021008250354000_r41","first-page":"1225","article-title":"Potential risk factors for nivolumab-induced thyroid dysfunction","volume":"31","author":"Yamazaki","year":"2017","journal-title":"In Vivo"},{"key":"2025021008250354000_r42","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1084\/jem.178.3.793","article-title":"I-E+ nonobese diabetic mice develop insulitis and diabetes","volume":"178","author":"Podolin","year":"1993","journal-title":"J. Exp. Med."},{"key":"2025021008250354000_r43","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1002\/eji.1830271117","article-title":"Analysis of susceptibility of NOD mice to spontaneous and experimentally induced thyroiditis","volume":"27","author":"Damotte","year":"1997","journal-title":"Eur. J. Immunol."},{"key":"2025021008250354000_r44","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1146\/annurev.immunol.23.021704.115643","article-title":"The NOD mouse: a model of immune dysregulation","volume":"23","author":"Anderson","year":"2005","journal-title":"Annu. Rev. Immunol."},{"key":"2025021008250354000_r45","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/j.cell.2020.05.017","article-title":"Intratumoral CD4+ T cells mediate anti-tumor cytotoxicity in human bladder cancer","volume":"181","author":"Oh","year":"2020","journal-title":"Cell"},{"key":"2025021008250354000_r46","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1038\/s41591-019-0522-3","article-title":"Clonal replacement of tumor-specific T cells following PD-1 blockade","volume":"25","author":"Yost","year":"2019","journal-title":"Nat. Med."},{"key":"2025021008250354000_r47","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"2025021008250354000_r48","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1006\/jaut.2001.0544","article-title":"Autoantibody patterns in diabetes-prone NOD mice and in standard C57BL\/6 mice","volume":"17","author":"Quintana","year":"2001","journal-title":"J. Autoimmun."},{"key":"2025021008250354000_r49","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1084\/jem.20050693","article-title":"Modifier loci condition autoimmunity provoked by Aire deficiency","volume":"202","author":"Jiang","year":"2005","journal-title":"J. Exp. Med."},{"key":"2025021008250354000_r50","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/s41586-019-1162-y","article-title":"Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy","volume":"569","author":"Perez-Ruiz","year":"2019","journal-title":"Nature"},{"key":"2025021008250354000_r51","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1056\/NEJMra0707449","article-title":"Interleukin-17 and type 17 helper T cells","volume":"361","author":"Miossec","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"2025021008250354000_r52","doi-asserted-by":"crossref","first-page":"3642","DOI":"10.4049\/jimmunol.1501921","article-title":"Effector \u03b3\u03b4 T cell differentiation relies on master but not auxiliary Th cell transcription factors","volume":"196","author":"Barros-Martins","year":"2016","journal-title":"J. Immunol."},{"key":"2025021008250354000_r53","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.cell.2006.07.035","article-title":"The orphan nuclear receptor ROR\u03b3t directs the differentiation program of proinflammatory IL-17+ T helper cells","volume":"126","author":"Ivanov","year":"2006","journal-title":"Cell"},{"key":"2025021008250354000_r54","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1365-2567.2011.03522.x","article-title":"Interleukin-23: as a drug target for autoimmune inflammatory diseases","volume":"135","author":"Tang","year":"2012","journal-title":"Immunology"},{"key":"2025021008250354000_r55","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jaut.2017.11.006","article-title":"Innately versatile: \u03b3\u03b417 T cells in inflammatory and autoimmune diseases","volume":"87","author":"Papotto","year":"2018","journal-title":"J. Autoimmun."},{"key":"2025021008250354000_r56","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3109\/08830185.2014.954698","article-title":"Tc17 cells in immunity and systemic autoimmunity","volume":"34","author":"Liang","year":"2015","journal-title":"Int. Rev. Immunol."},{"key":"2025021008250354000_r57","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.4110\/in.2020.20.e6","article-title":"Il-17-producing cells in tumor immunity: friends or foes?","volume":"20","author":"Kuen","year":"2020","journal-title":"Immune Netw."},{"key":"2025021008250354000_r58","doi-asserted-by":"crossref","first-page":"4810","DOI":"10.1210\/en.2009-0417","article-title":"Morphological ultrasound microimaging of thyroid in living mice","volume":"150","author":"Mancini","year":"2009","journal-title":"Endocrinology"},{"key":"2025021008250354000_r59","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J. Clin. Invest."},{"key":"2025021008250354000_r60","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1158\/0008-5472.CAN-16-2324","article-title":"Immune toxicities elicted by CTLA-4 blockade in cancer patients are associated with early diversification of the T-cell repertoire","volume":"77","author":"Oh","year":"2017","journal-title":"Cancer Res."},{"key":"2025021008250354000_r61","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1016\/j.celrep.2019.05.064","article-title":"Single-cell transcriptomics identifies the adaptation of Scart1+ V\u03b36+ T cells to skin residency as activated effector cells","volume":"27","author":"Tan","year":"2019","journal-title":"Cell Rep."},{"key":"2025021008250354000_r62","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/s41423-021-00644-5","article-title":"Local and systemic effects of IL-17 in joint inflammation: a historical perspective from discovery to targeting","volume":"18","author":"Miossec","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"2025021008250354000_r63","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.immuni.2006.01.001","article-title":"TGF\u03b2 in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells","volume":"24","author":"Veldhoen","year":"2006","journal-title":"Immunity"},{"key":"2025021008250354000_r64","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/s40425-019-0711-0","article-title":"Concurrent therapy with immune checkpoint inhibitors and TNF\u03b1 blockade in patients with gastrointestinal immune-related adverse events","volume":"7","author":"Badran","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"2025021008250354000_r65","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.it.2021.02.006","article-title":"Predicting and preventing immune checkpoint inhibitor toxicity: targeting cytokines","volume":"42","author":"Kang","year":"2021","journal-title":"Trends Immunol."},{"key":"2025021008250354000_r66","doi-asserted-by":"crossref","first-page":"178.19","DOI":"10.4049\/jimmunol.200.Supp.178.19","article-title":"Development of syngeneic NOD tumor models to study tumor immunity in autoimmune-prone mice","volume":"200","author":"Young","year":"2018","journal-title":"J. Immunol."},{"key":"2025021008250354000_r67","doi-asserted-by":"crossref","first-page":"5894","DOI":"10.1038\/onc.2008.268","article-title":"How tumours escape mass destruction","volume":"27","author":"Stewart","year":"2008","journal-title":"Oncogene"},{"key":"2025021008250354000_r68","doi-asserted-by":"crossref","first-page":"6034","DOI":"10.1158\/1078-0432.CCR-14-0879","article-title":"MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitro","volume":"20","author":"Angell","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"2025021008250354000_r69","doi-asserted-by":"crossref","first-page":"387","DOI":"10.6004\/jnccn.2022.0020","article-title":"Management of Immunotherapy-Related Toxicities, version 1.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Thompson","year":"2022","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"2025021008250354000_r70","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1186\/s40425-019-0779-6","article-title":"Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis. [Published erratum appears in 2020 J. Immunother. Cancer 8: e0779-6corr1.]","volume":"7","author":"Xing","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"2025021008250354000_r71","doi-asserted-by":"crossref","DOI":"10.1007\/s00262-021-03128-7","article-title":"Associations between immune-related thyroid dysfunction and efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis","author":"Cheung","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"key":"2025021008250354000_r72","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1089\/thy.2019.0250","article-title":"PD-L1 inhibitor-induced thyroiditis is associated with better overall survival in cancer patients","volume":"30","author":"Kotwal","year":"2020","journal-title":"Thyroid"},{"key":"2025021008250354000_r73","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.3390\/ijms17091433","article-title":"Targeting the tumor microenvironment: the protumor effects of IL-17 related to cancer type","volume":"17","author":"Fabre","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"2025021008250354000_r74","doi-asserted-by":"crossref","first-page":"e20190297","DOI":"10.1084\/jem.20190297","article-title":"The role of interleukin-17 in tumor development and progression","volume":"217","author":"Zhao","year":"2020","journal-title":"J. Exp. Med."},{"key":"2025021008250354000_r75","doi-asserted-by":"crossref","first-page":"e001895","DOI":"10.1136\/jitc-2020-001895","article-title":"Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer. [Published erratum appears in 2021 J. Immunother. Cancer 9: e001895corr1.]","volume":"9","author":"Liu","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"2025021008250354000_r76","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"2025021008250354000_r77","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/BF03347816","article-title":"Infiltrating \u03b3\/\u03b4 T-cell receptor-positive lymphocytes in Hashimoto\u2019s thyroiditis, Graves\u2019 disease and papillary thyroid cancer","volume":"18","author":"Paolieri","year":"1995","journal-title":"J. Endocrinol. Invest."},{"key":"2025021008250354000_r78","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/ni.3726","article-title":"IL-17+ \u03b3\u03b4 T cells as kick-starters of inflammation","volume":"18","author":"Papotto","year":"2017","journal-title":"Nat. Immunol."},{"key":"2025021008250354000_r79","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.immuni.2009.08.001","article-title":"Interleukin-1 and IL-23 induce innate IL-17 production from \u03b3\u03b4 T cells, amplifying Th17 responses and autoimmunity","volume":"31","author":"Sutton","year":"2009","journal-title":"Immunity"},{"key":"2025021008250354000_r80","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s40425-015-0081-1","article-title":"Baseline circulating IL-17 predicts toxicity while TGF-\u03b21 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma","volume":"3","author":"Tarhini","year":"2015","journal-title":"J. Immunother. Cancer"},{"key":"2025021008250354000_r81","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1479-5876-7-35","article-title":"CTLA4 blockade increases Th17 cells in patients with metastatic melanoma","volume":"7","author":"von Euw","year":"2009","journal-title":"J. Transl. Med."},{"key":"2025021008250354000_r82","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1006\/jaut.1999.0272","article-title":"Spontaneous autoimmune thyroiditis in NOD.H-2h4 mice","volume":"12","author":"Braley-Mullen","year":"1999","journal-title":"J. Autoimmun."},{"key":"2025021008250354000_r83","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1210\/js.2017-00400","article-title":"Aberrant iodine autoregulation induces hypothyroidism in a mouse strain in the absence of thyroid autoimmunity","volume":"2","author":"McLachlan","year":"2017","journal-title":"J. Endocr. Soc."},{"key":"2025021008250354000_r84","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1210\/en.2016-1875","article-title":"Genes outside the major histocompatibility complex locus are linked to the development of thyroid autoantibodies and thyroiditis in NOD.H2h4 mice","volume":"158","author":"McLachlan","year":"2017","journal-title":"Endocrinology"},{"key":"2025021008250354000_r85","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1365-2265.2005.02424.x","article-title":"Investigations of thyroid hormones and antibodies based on a community health survey: the Busselton thyroid study","volume":"64","author":"O\u2019Leary","year":"2006","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"2025021008250354000_r86","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1365-2265.1977.tb01340.x","article-title":"The spectrum of thyroid disease in a community: the Whickham survey","volume":"7","author":"Tunbridge","year":"1977","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"2025021008250354000_r87","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1210\/jcem.87.2.8182","article-title":"Serum TSH, T4, and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III)","volume":"87","author":"Hollowell","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2025021008250354000_r88","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41417-020-0183-x","article-title":"Revisiting the role of CD4+ T cells in cancer immunotherapy\u2014new insights into old paradigms","volume":"28","author":"Tay","year":"2021","journal-title":"Cancer Gene Ther."},{"key":"2025021008250354000_r89","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1210\/en.2011-1356","article-title":"Induction of autoimmune thyroiditis by depletion of CD4+CD25+ regulatory T cells in thyroiditis-resistant IL-17, but not interferon-\u03b3 receptor, knockout nonobese diabetic-H2h4 mice","volume":"152","author":"Horie","year":"2011","journal-title":"Endocrinology"},{"key":"2025021008250354000_r90","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.cell.2016.08.069","article-title":"Loss of IFN-\u03b3 pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy","volume":"167","author":"Gao","year":"2016","journal-title":"Cell"},{"key":"2025021008250354000_r91","doi-asserted-by":"crossref","first-page":"12335","DOI":"10.1038\/ncomms12335","article-title":"Interdependent IL-7 and IFN-\u03b3 signalling in T-cell controls tumour eradication by combined \u03b1-CTLA-4+\u03b1-PD-1 therapy","volume":"7","author":"Shi","year":"2016","journal-title":"Nat. Commun."}],"container-title":["The Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/209\/4\/696\/61468031\/ji2200244.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/209\/4\/696\/61468031\/ji2200244.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T03:25:31Z","timestamp":1739157931000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jimmunol\/article\/209\/4\/696\/7924790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":91,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,8,15]]}},"URL":"https:\/\/doi.org\/10.4049\/jimmunol.2200244","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.01.19.476844","asserted-by":"object"}]},"ISSN":["0022-1767","1550-6606"],"issn-type":[{"value":"0022-1767","type":"print"},{"value":"1550-6606","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,8]]},"published":{"date-parts":[[2022,8]]}}}